Pyxis Oncology Inc 宣布,其与Keytruda联合进行的Micvo 1/2期临床试验的最新数据,预计将在2026年下半年更新。这一进展备受业界关注,可能为相关治疗领域带来新的突破。
Pyxis Oncology Inc 宣布,其与Keytruda联合进行的Micvo 1/2期临床试验的最新数据,预计将在2026年下半年更新。这一进展备受业界关注,可能为相关治疗领域带来新的突破。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.